Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 138 record(s)

Req # A-2020-000302

Adverse Reaction Reports (AERs). Report numbers: E2B_02117433, E2B_02222419, E2B_02244913, E2B_02262499, E2B_02325016, E2B_02342497, E2B_02345476, E2B_02351697, E2B_02396498, 000726087, 000726137.

Organization: Health Canada

135 page(s)
November 2020

Req # A-2020-000328

Adverse Reaction Reports (AERs) for Vyvanse. Report numbers: 000731357, 000733940, E2B_02973620, E2B_02969928, E2B_02969837, E2B_02969820, E2B_02963971, E2B_02963934, E2B_02963103, E2B_02963088, E2B_02941816, E2B_02921064.

Organization: Health Canada

150 page(s)
November 2020

Req # A-2020-000349

Adverse Reaction Reports (AERs) for CLOPIDOGREL BISULFATE. Report numbers: E2B_02661867, E2B_02677415, 729458.

Organization: Health Canada

123 page(s)
November 2020

Req # A-2020-000358

Adverse Reaction Reports (AERs) for LEFLUNOMIDE. Report numbers: E2B_02836359, E2B_02865727, E2B_02865885, E2B_02836441, E2B_02878692, E2B_02451441, E2B_02883657, E2B_02866159, E2B_02880293, E2B_02867503, E2B_02871984, E2B_00471514, E2B_02875200, E2B_02886167, E2B_02872071.

Organization: Health Canada

313 page(s)
November 2020

Req # A-2020-000362

Adverse Reaction Reports (AERs) for RIFAMPICIN. Report numbers: 727731, E2B_02714659, E2B_02733268.

Organization: Health Canada

63 page(s)
November 2020

Req # A-2020-000363

Adverse Reaction Report (AER) for RAMIPRIL. Report number: E2B_02980549.

Organization: Health Canada

24 page(s)
November 2020

Req # A-2020-000409

Adverse Reaction Reports (AERs). Report numbers: E2B_03042685, E2B_03043235, E2B_03043502, E2B_03046113.

Organization: Health Canada

62 page(s)
November 2020

Req # A-2020-000412

Adverse Reaction Reports (AERs). Report numbers: E2B_03048477, E2B_03048789.

Organization: Health Canada

50 page(s)
November 2020

Req # A-2020-000413

Adverse Reaction Reports (AERs). Report numbers: E2B_03028565, E2B_03028567, E2B_03028605, E2B_03028607.

Organization: Health Canada

74 page(s)
November 2020

Req # A-2020-000422

Adverse Reaction Report (AER) for botulinum toxin. Report number: E2B_03001113.

Organization: Health Canada

7 page(s)
November 2020
Date modified: